Use of sirolimus in patients with primary steroid-resistant nephrotic syndrome;Uso del sirolimus en pacientes con síndrome nefrótico córtico-resistente primario

Nefrologia

Volumn 32, Issue 3, 2012, Pages 321-328

  Liern, Miguel ^a   de Reyes, Verónica ^a   Fayad, Alicia ^a   Vallejo, Graciela ^a  

^a HOSPITAL DE NIÑOS RICARDO GUTIÉRREZ   (Argentina)

Author keywords

Focal and segmental glomerulosclerosis; Sirolimus; Steroid resistant nephrotic syndrome

Indexed keywords

CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN;

ADOLESCENT; ARTICLE; CHILD; CLINICAL TRIAL; COHORT ANALYSIS; DRUG RESISTANCE; FEMALE; FOCAL GLOMERULOSCLEROSIS; FOLLOW UP; HUMAN; KIDNEY; MALE; NEPHROTIC SYNDROME; PATHOLOGY; PROSPECTIVE STUDY; PROTEINURIA; REMISSION; TREATMENT OUTCOME;

ADOLESCENT; ADRENAL CORTEX HORMONES; CHILD; COHORT STUDIES; DRUG RESISTANCE; FEMALE; FOLLOW-UP STUDIES; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; MALE; NEPHROTIC SYNDROME; PROSPECTIVE STUDIES; PROTEINURIA; REMISSION INDUCTION; SIROLIMUS; TREATMENT OUTCOME;

EID: 84864498891     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: 10.3265/Nefrologia.pre2012.Jan.11093     Document Type: Article

References (36)

1. Srivastava T, Somon SD. High incidence of focal segmental glomerulosclerosis in nephrotic syndrome of childhood. Pediatr Nephrol 1999;13:13-8.
2. Alexopoulos E, Stongou M. Factors influencing the course and the response to treatment in primary focal segmental glomeruloesclerosis. Nephrol Dial Transplant 2000;15:1348- 56.
3. Korber SM. Primary focal segmental glomeruloesclerosis. J Am Soc Nephrol 1998;9:1333-40.
4. Fogo AB. Progression and potential regression of glomeruloesclerosis. Kidney Int 2001;59:804-19.
5. Cattran DC, Ponduranga R. Long-term outcome in children and adults with classic focal segmental glomeruloesclerosis. Am J Kidney Dis 1998;32:72-9.
6. Velosa J, Holley K. Significance of proteinuria on the outcome of renal function in patients with focal segmental glomeruloesclerosis. Mayo Clin Proc 1983;58:568-77.
7. Schweda F, Liebl R. Tacrolimus treatment for steroid and cyclosporine- resistant nephrotic syndrome. Nephrol DialTransplant 1997;12:2433-5.
8. Meyrier A. Treatment of idiopathic nephrosis by immunophillin modulation. Nephrol Dial Transplant 2003;18(Suppl 6):79-86.
9. Gipson DS, Chin H, Presler TP, Jennette C, Ferris ME, Massengill S, et al. Differential Risk of Remission and ESRD in Childhood FSGS. Pediatr Nephrol 2006;21:344-9.
10. Zamora, Peña A, Mendizábal S, Bedoya R, Vilalta R, Torra R. Síndrome nefrótico idiopático en el niño. Nefrologia 2007;27(Suppl 2):33-44.
11. Simón J, Zamora I. Tratamiento del síndrome nefrótico del niño en los inicios del siglo XXI. Nefrologia 2003;23:287-90.
12. Hodson EM, Knight JF, Willis NS, Craig JC. Corticosteroid therapy for nephrotic syndrome in children (Cochrane Review). En: The Cochrane Library, Issue 2. Oxford: Update Software: 2008.
13. van Husen M, Kemper M. New therapies in steroid-sensitive and steroid- resistant idiopathic nephrotic syndrome. Pediatr Nephrol 2011;26:881-92.
14. Cattran DC, Alexopoulos E. Cyclosporine in idiopathic glomerular disease associated with the nephrotic syndrome: Workshop recommendations. Kidney International 2007;72:1429-47.
15. Aucellia F, Bisceglia L. A genetic viewpoint of focal glomerular sclerosis: from genes to glomerular pathophysiology. G Ital Nefrol 2003;20(4):356-67.
16. Tumlin JA, Miller D, Near M, Selvaraj S, Hennigar R, Guasch A. A prospective, open-label trial of sirolimus in the treatment of focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2006;1:109- 16.
17. Lavjay B, Rajendra R. Experience with tacrolimus in children with steroid- resistant nephrotic syndrome. Pediatr Nephrol2009;24:1517-23.
18. Durkan A, Hodson EM, Willis NS, Craig JC. Non-corticosteroid treatment for nephrotic syndrome in children. Cochrane Systematic,review at www.cochrane.org/reviews/en/ab002290.html, 2006.
19. Serkova N, Christians U. Transplantation: toxicokinetics and mechanisms of toxicity of cyclosporine and macrolides. Curr OpinInvestig Drugs 2003;4:1287-96.
20. Oppenheimer F, Alonso A, Arias M, Campistol JM, González Molina M, González Posada JM, et al. Manejo de sirolimus en la práctica clínica. Nefrologia 2006;26 Suppl 2:64-93.
21. Fervenza FC, Fitzpatrick PM, Mertz J, Erickson SB, Liggett S, Popham S, et al. Acute rapamycin nephrotoxicity in native kidneys of patients withchronic glomerulopathies. Nephrol Dial Transplant 2004;19(5):1288-92.
22. Augustine JJ, Knauss TC, Schulak JA, Bodziak KA, Siegel C, Hricik DE. Comparative Effects of Sirolimus and Mycophenolate Mofetil onErythropoiesis in Kidney Transplant Patients. Am J Transplant 2004;4(12): 2001-6.
23. Thaunat O, Beaumont C, Chatenoud L, Lechaton S, Mamzer- Bruneel MF, Varet B, et al. Anemia after Late Introduction of Sirolimus May Correlate with Biochemical Evidence of a Chronic Inflammatory State. Transplantation 2005;80(9):1212-9.
24. Van Biesen W, Vanholder R, Veys N, Verbeke F, Lameire N. Efficacy of erythropoietin administration in the treatment of anemia immediately after renal transplantation. Transplantation 2005;79(3):367-8.
25. Katia S, Annie M, Judith F, Etienne L. Role of the renin-angiotensin system in primitive erythropoiesis in the chick embryo blood. Blood 2005;105:103-10.
26. Blum CB. Effects of sirolimus on lipids in renal allograft recipients: an analysis using the Framingham risk model. Am J Transplant 2002;2(6):551-9.
27. Flechner SM, Feng J, Mastroianni B, Savas K, Arnovitz J, Moneim H, et al. The effect of 2-gram versus 1-gram concentration controlled mycophenolate mofetil on renal transplant outcomes using sirolimus-based calcineurin inhibitor drug-free immunosuppression. Transplantation 2005;79(8):926-34.
28. Letavernier E, Bruneval P, Mandet C, Van Huyen JP, Péraldi MN, Helal I, et al. High sirolimus levels may induce focal segmental glomerulosclerosis de novo. Clin J Am Soc Nephrol 2007;2(2):198-9.
29. Cho ME, Hurley J, Kopp J, Flechner SM, Feng J, Mastroianni B, Savas K. sirolimus therapy of focal segmental glomerulosclerosis Is Associated with nephrotoxicity Am J Kidney Dis 2007;49(2)310-7.
30. Chueh SC, Kahan BD. Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine-based immunosuppressive regimen: incidence, risk factors, progression, and prognosis. Transplantation 2003;76(2):375-82.
31. Liern M, Diéguez S, De Reyes V, Vallejos G, Canepa C. Efecto antiproteinúrico del uso aditivo de enalapril y losartan en pacientes pediátricos normotensos con proteinuria. Rev Esp Nefrol 2004;24(6):553- 8.
32. Van Gelder T, Ter Meulen CG, Hene R, Weimar W, Hoitsma A. Oral ulcers in kidney transplant recipients treated with sirolimus and mycophenolate mofetil. Transplantation 2003;75(6):788-91.
33. Chun M, Korbet J, Schwartz M, Lewis E. Focal Segmental glomerulosclerosis in nephrotic adults: presentation, prognosis, andresponse to therapy of the histologic variants. J Am Soc Nephrol 2004;15:2169-77.
34. Barisoni L, Appel G, Seigle R, D'Agati V. Idiopathic collapsing focal segmental glomerulosclerosis: A clinicopathologic study. Kidney Int 1996;50:1734-46.
35. Bazzi C, Petrini C, Rizza V, Napodano P, Paparella M, Arrigo G, et al. Fractional excretion of IgG predicts renal outcome and response to therapy in primary focal segmental glomerulosclerosis: a pilot study. Am J Kidney Dis 2003;41:328-35.
36. Russo D. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis 2001;38:18-25.